Biosimilar Testing and Development Services Market Report 2024 (Global Edition)

Global Biosimilar Testing and Development Services Market Report 2024 Market Size Split by Type (Pharmacokinetics Assay, Immunogenicity Testing, Others), by End User (Pharmaceutical and Biopharmaceuti...

Biosimilar Testing and Development Services Market Report Description

We have various report editions of Biosimilar Testing and Development Services Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Biosimilar Testing and Development Services Market Insights Video

Competitive Landscape of the Biosimilar Testing and Development Service Market

The competitive landscape of the Biosimilar Testing and Development Service Market is characterized by several key players offering comprehensive testing and development services for biosimilar products. Major companies such as SGS SA, Eurofins Scientific, and Charles River Laboratories International, Inc. dominate the market, leveraging their expertise and global presence. Additionally, smaller players like BioOutsource Ltd. and WuXi AppTec contribute to the competitive landscape, offering specialized services and innovative solutions. Overall, intense competition drives innovation and quality assurance in the market.

September 2021: Samsung Bioepis and Biogen have jointly declared that the Food and Drug Administration (FDA) has granted approval for BYOOVIZ (ranibizumab-nuna), a biosimilar to LUCENTIS (ranibizumab), designated for treating neovascular age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. BYOOVIZ stands as the inaugural ophthalmology biosimilar to receive FDA approval in the United States.

(Source: https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11 )

Top Companies Market Share in Biosimilar Testing and Development Services Industry: (In no particular order of Rank)

• SGS SA (Switzerland)
• Eurofins Scientific (Luxembourg)
• Charles River Laboratories International
• Inc. (United States)
• Sartorius AG (Germany)
• Intertek Group plc (United Kingdom)
• PPD
• Inc. (United States)
• ICON plc (Ireland)
• WuXi AppTec (China)
• BioOutsource Ltd. (United Kingdom)
• Syneos Health
• Inc. (United States)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Biosimilar Testing and Development Service Market

Which Region Dominates the Biosimilar Testing and Development Service Market in 2024?

According to Cognitive Market Research, North America commands the largest market share in the Biosimilar Testing and Development Service Market due to several factors. The region boasts a robust regulatory framework and favorable reimbursement policies, facilitating biosimilar development. Additionally, high healthcare expenditure and a large patient pool drive demand for cost-effective therapies, stimulating market growth. Moreover, the presence of key market players, advanced healthcare infrastructure, and extensive research and development activities further contribute to North America's dominance in the biosimilar testing and development services sector.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is experiencing the fastest Compound Annual Growth Rate (CAGR) in the Biosimilar Testing and Development Service Market due to several reasons. This growth is propelled by increasing healthcare expenditure, rising prevalence of chronic diseases, and expanding access to healthcare across the region. Moreover, favorable government initiatives, supportive regulatory frameworks, and a large pool of skilled workforce contribute to the rapid expansion of biosimilar testing and development services in Asia Pacific, making it a key growth market in the industry.

The current report Scope analyzes Biosimilar Testing and Development Services Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Biosimilar Testing and Development Services

According to Cognitive Market Research, the global Biosimilar Testing and Development Service market size was estimated at USD 2651.00 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1060.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Biosimilar Testing and Development Service market with a market size of USD 836.66 million in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period. The demand is amplified by the nation's High healthcare expenditure.
• The Canada Biosimilar Testing and Development Service market had a market share of USD 127.25 million in 2024 and is projected to grow at a CAGR of 11.5% during the forecast period. Thi is due to advanced healthcare infrastructure.
• The Mexico Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD 96.50 million in 2024.

Europe Biosimilar Testing and Development Services

According to Cognitive Market Research, the global Biosimilar Testing and Development Service market size was estimated at USD 2651.00 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 795.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.0% from 2024 to 2031.

• The United Kingdom Biosimilar Testing and Development Service market had a market share of USD 133.61 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. In the UK, Biosimilar Testing and Development Service sales witness an upswing due to increased investment in biosimilar development.
• The France Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 73.17 million in 2024.
• According to Cognitive Market Research, the Germany Biosimilar Testing and Development Service market size was valued at USD 157.47 million in 2024 and is projected to grow at a CAGR of 11.2% during the forecast period. In Germany, Biosimilar Testing and Development Service sales surged due to growing demand for affordable healthcare solutions.
• The Italy Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 10.4% during the forecast period, with a market size of USD 68.40 million in 2024.
• The Russia Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 123.27 million in 2024.
• The Spain Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 10.1% during the forecast period with a market size of USD 65.21 million in 2024
• The Luxembourg Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 24.65 million in 2024.
• The Portugal Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 10.8% during the forecast period, with a market size of USD 16.70 million in 2024.
• The Greece Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 11.3% during the forecast period, with a market size of USD 9.54 million in 2024.
• Rest of Europe's Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 123.27 million in 2024.

Asia Pacific Biosimilar Testing and Development Services

According to Cognitive Market Research, the global Biosimilar Testing and Development Service market size was estimated at USD 2651.00 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 609.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Biosimilar Testing and Development Service market size was valued at USD 274.38 million in 2024 and is projected to grow at a CAGR of 14.0% during the forecast period. Biosimilar Testing and Development Service sales surge in China due to increasing healthcare expenditure.
• The Japan Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 84.14 million in 2024.
• The India Biosimilar Testing and Development Service market had a market share of USD 73.17 million in 2024 and is projected to grow at a CAGR of 16.3% during the forecast period. This is due to rising prevalence of chronic diseases.
• The South Korea Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 13.6% during the forecast period, with a market size of USD 60.97 million in 2024.
• The Australia Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 14.2% during the forecast period, with a market size of USD 31.71 million in 2024.
• The South East Asia Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 15.5% during the forecast period, with a market size of USD 42.07 million in 2024.
• The Rest of Asia Pacific Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 14.3% during the forecast period, with a market size of USD 43.29 million in 2024.

South America Biosimilar Testing and Development Services

According to Cognitive Market Research, the global Biosimilar Testing and Development Service market size was estimated at USD 2651.00 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 132.55 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Biosimilar Testing and Development Service market size was valued at USD 56.73 million in 2024 and is projected to grow at a CAGR of 12.5% during the forecast period. Biosimilar Testing and Development Service sales flourish in Brazil due to increasing healthcare expenditure.
• Argentina Biosimilar Testing and Development Service market had a market share of USD 22.27 million in 2024 and is projected to grow at a CAGR of 12.8% during the forecast period. This is due to rising prevalence of chronic diseases.
• Colombia Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 11.7% during the forecast period with a market size of USD 11.80 million in 2024.
• Peru Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 12.1% during the forecast period with a market size of USD 10.87 million in 2024.
• Chile Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 12.2% during the forecast period with a market size of USD 9.54 million in 2024.
• The Rest of Latin America Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 11.0% during the forecast period, with a market size of USD 21.34 million in 2024.

Middle East and Africa Biosimilar Testing and Development Services

According to Cognitive Market Research, the global Biosimilar Testing and Development Service market size was estimated at USD 2651.00 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 53.02 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.2% from 2024 to 2031.

• The GCC Countries Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 13.0% during the forecast period with a market size of USD 22.69 million in 2024. Biosimilar Testing and Development Service sales flourish due to increasing healthcare investments.
• The Egypt Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 12.5% during the forecast period, with a market size of USD 5.57 million in 2024.
• The South Africa Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 13.2% during the forecast period, with a market size of USD 8.38 million in 2024. Biosimilar Testing and Development Service sales flourish in South Africa due to rising demand for affordable treatment options.
• The Turkey Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 4.56 million in 2024.
• The Nigeria Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 11.3 million in 2024.
• The Rest of MEA Biosimilar Testing and Development Service market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD 6.26 million in 2024.

Biosimilar Testing and Development Services Market Analysis

How are Segments Performing in the Global Biosimilar Testing and Development Service Market?

Biosimilar Testing and Development Service Market Type Segment Analysis

According to Cognitive Market Research, Pharmacokinetics Assay stands out as the dominating category. Pharmacokinetics assays have captured the largest market share in the Biosimilar Testing and Development Service Market due to their critical role in assessing the similarity between biosimilars and reference biologics. These assays provide valuable data on the absorption, distribution, metabolism, and excretion of drugs, helping to establish bioequivalence. With regulatory agencies placing a strong emphasis on pharmacokinetic studies for biosimilar approval, the demand for pharmacokinetics assay services has surged, driving their dominance in the biosimilar testing and development services market.

Immunogenicity testing is experiencing the highest Compound Annual Growth Rate (CAGR) in the Biosimilar Testing and Development Service Market due to its crucial role in assessing the immune response to biosimilar products. With regulatory agencies increasingly emphasizing the importance of immunogenicity assessment for biosimilar approval, the demand for these tests has surged. Additionally, as biosimilar development progresses, ensuring minimal immunogenicity and comparable safety to reference biologics becomes paramount, further driving the growth of immunogenicity testing services in the market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Biosimilar Testing and Development Services Industry. Request a Free Sample PDF!

Biosimilar Testing and Development Service Market End User Segment Analysis

According to Cognitive Market Research, the dominating category is Pharmaceutical and Biopharmaceutical Companies. Pharmaceutical and biopharmaceutical companies are the largest end users in the Biosimilar Testing and Development Service Market due to several factors. These companies are at the forefront of biosimilar development, investing heavily in research and development to bring new biologic products to market. They require comprehensive testing and development services to ensure the safety, efficacy, and compliance of biosimilars with regulatory standards. Consequently, they represent the primary clientele for biosimilar testing and development service providers, capturing the largest market share.

Contract Research Organizations (CROs) are witnessing the highest Compound Annual Growth Rate (CAGR) in the Biosimilar Testing and Development Service Market due to several factors. As pharmaceutical companies increasingly outsource their research and development activities to specialized service providers, CROs are experiencing a surge in demand for biosimilar testing and development services. Moreover, the flexibility, cost-effectiveness, and expertise offered by CROs appeal to companies seeking to streamline their operations and accelerate biosimilar development, driving their rapid growth in the market.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion